Novel function of histamine signaling via histamine receptors in cholesterol and bile acid metabolism: Histamine H2 receptor protects against nonalcoholic fatty liver disease

Pathology International

Volumn 66, Issue 7, 2016, Pages 376-385

  Yamada, Sohsuke ^a,b   Guo, Xin ^a,b,c   Wang, Ke Yong ^b   Tanimoto, Akihide ^a   Sasaguri, Yasuyuki ^d  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c Medical University   (China)

^d FUKUOKA WAJIRO HOSPITAL   (Japan)

Author keywords

bile acid (BA) metabolism; cholesterol metabolism; cholic acid (CA) diet; high cholesterol diet; histamine; histamine receptor (HR); nonalcoholic fatty liver disease (NAFLD)

Indexed keywords

BILE ACID; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ESTERASE; CHOLIC ACID; HIGH DENSITY LIPOPROTEIN; HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE ACID METABOLISM; BIOACCUMULATION; BLOOD ANALYSIS; CHOLESTEROL DIET; CHOLESTEROL INTAKE; CHOLESTEROL METABOLISM; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; EFFUSION; FECES; INTESTINAL REABSORPTION; INTESTINE ABSORPTION; JEJUNUM; KNOCKOUT MOUSE; LIPOPROTEIN BLOOD LEVEL; LIVER; LIVER INJURY; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WILD TYPE;

EID: 84977576154     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/pin.12423     Document Type: Article

References (44)

1. Neuschwander-Tetri BA. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci 2005; 330: 326–35.
2. Guo X, Yamada S, Tanimoto A et al. Overexpression of peroxiredoxin 4 attenuates atherosclerosis in apolipoprotein E knockout mice. Antioxid Redox Signal 2012; 17: 1362–75.
3. Nabeshima A, Yamada S, Guo X et al. Peroxiredoxin 4 protects against nonalcoholic steatohepatitis and type 2 diabetes in a nongenetic mouse model. Antioxid Redox Signal 2013; 19: 1983–98.
4. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 2008; 75: 721–8.
5. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221–31.
6. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413–9.
7. Hernández Vallejo SJ, Alqub M, Luquet S et al. Short-term adaptation of postprandial lipoprotein secretion and intestinal gene expression to a high-fat diet. Am J Physiol Gastrointest Liver Physiol 2009; 296: G782–92.
8. Iqbal J, Hussain MM. Intestinal lipid absorption. Am J Physiol Endocrinol Metab 2009; 296: E1183–94.
9. Nawata A, Noguchi H, Mazaki Y et al. Overexpression of peroxiredoxin 4 affects intestinal function in a dietary mouse model of nonalcoholic fatty liver disease. PLoS ONE 2016; 11: e0152549.
10. Wang KY, Tanimoto A, Yamada S et al. Histamine regulation in glucose and lipid metabolism via histamine receptors: model for nonalcoholic steatohepatitis in mice. Am J Pathol 2010; 177: 713–23.
11. Murata Y, Tanimoto A, Wang K-Y et al. Granulocyte macrophage–colony stimulating factor increases the expression of histamine and histamine receptors in monocytes/macrophages in relation to arteriosclerosis. Arterioscler Thromb Vasc Biol 2005; 25: 430–5.
12. Sasaguri Y, Wang KY, Tanimoto A et al. Role of histamine produced by bone marrow-derived vascular cells in pathogenesis of atherosclerosis. Circ Res 2005; 96: 974–81.
13. Tanimoto A, Sasaguri Y, Ohtsu H. Histamine network in atherosclerosis. Trends Cardiovasc Med 2006; 16: 280–4.
14. Wang KY, Tanimoto A, Guo X et al. Histamine deficiency decreases atherosclerosis and inflammatory response in apolipoprotein E knockout mice independently of serum cholesterol level. Arterioscler Thromb Vasc Biol 2011; 31: 800–7.
15. Takagishi T, Sasaguri Y, Nakano R et al. Expression of the histamine H1 receptor gene in relation to atherosclerosis. Am J Pathol 1995; 146: 981–8.
16. Tanimoto A, Wang KY, Murata Y et al. Histamine upregulates the expression of inducible nitric oxide synthase in human intimal smooth muscle cells via histamine H1 receptor and NF-κB signaling pathway. Arterioscler Thromb Vasc Biol 2007; 27: 1556–61.
17. Yamada S, Wang KY, Tanimoto A et al. Histamine receptors expressed in circulating progenitor cells have reciprocal actions in ligation-induced arteriosclerosis. Pathol Int 2013; 63: 435–47.
18. Yamada S, Wang KY, Tanimoto A, Sasaguri Y. Novel function of histamine signaling in hyperlipidemia-induced atherosclerosis: Histamine H1 receptors protect and H2 receptors accelerate atherosclerosis. Pathol Int 2015; 65: 67–80.
19. Inoue I, Yanai K, Kitamura D et al. Impaired locomotor activity and exploratory behavior in mice lacking histamine H1 receptors. Proc Natl Acad Sci U S A 1996; 93: 13316–20.
20. Kobayashi T, Tonai S, Ishihara Y, Koga R, Okabe S, Watanabe T. Abnormal functional and morphological regulation of the gastric mucosa in histamine H2 receptor-deficient mice. J Clin Invest 2000; 105: 1741–9.
21. Wang DQ, Paigen B, Carey MC. Genetic factors at the enterocyte level account for variations in intestinal cholesterol absorption efficiency among inbred strains of mice. J Lipid Res 2001; 42: 1820–30.
22. Wang DQ, Tazuma S. Effect of β-muricholic acid on the prevention and dissolution of cholesterol gallstones in C57L/J mice. J Lipid Res 2002; 43: 1960–8.
23. Wang DQ, Carey MC. Measurement of intestinal cholesterol absorption by plasma and fecal dual-isotope ratio, mass balance, and lymph fistula methods in the mouse: an analysis of direct versus indirect methodologies. J Lipid Res 2003; 44: 1042–59.
24. Yamada S, Wang KY, Tanimoto A et al. Matrix metalloproteinase 12 accelerates the initiation of atherosclerosis and stimulates the progression of fatty streaks to fibrous plaques in transgenic rabbits. Am J Pathol 2008; 172: 1419–29.
25. Ding Y, Yamada S, Wang KY et al. Overexpression of peroxiredoxin 4 protects against high-dose streptozotocin-induced diabetes by suppressing oxidative stress and cytokines in transgenic mice. Antioxid Redox Signal 2010; 13: 1477–90.
26. Yamada S, Ding Y, Tanimoto A et al. Apoptosis signal-regulating kinase 1 deficiency accelerates hyperlipidemia-induced atheromatous plaques via suppression of macrophage apoptosis. Arterioscler Thromb Vasc Biol 2011; 31: 1555–64.
27. Tasaki T, Yamada S, Guo X et al. Apoptosis signal-regulating kinase 1 deficiency attenuates vascular injury-induced neointimal hyperplasia by suppressing apoptosis in smooth muscle cells. Am J Pathol 2013; 182: 597–609.
28. Noguchi H, Yamada S, Nabeshima A et al. Depletion of apoptosis signal-regulating kinase 1 prevents bile duct ligation-induced necro-inflammation and subsequent peribiliary fibrosis. Am J Pathol 2014; 184: 644–61.
29. Yamada S, Koyama T, Noguchi H et al. Marine hydroquinone zonarol prevents inflammation and apoptosis in dextran sulfate sodium-induced mice ulcerative colitis. PLoS One 2014; 9:e113509
30. Aqul A, Lopez AM, Posey KS et al. Hepatic entrapment of esterified cholesterol drives continual expansion of whole body sterol pool in lysosomal acid lipase-deficient mice. Am J Physiol Gastrointest Liver Physiol 2014; 307: G836–47.
31. Haines BE, Wiest O, Stauffacher CV. The increasingly complex mechanism of HMG-CoA reductase. Acc Chem Res 2013; 46: 2416–26.
32. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009; 89: 147–91.
33. Ferrebee CB, Dawson PA. Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids. Acta Pharm Sin B 2015; 5: 129–34.
34. Andrade RJ, Lucena MI, Martin-Vivaldi R et al. Acute liver injury associated with the use of ebrotidine, a new H2-receptor antagonist. J Hepatology 1999; 31: 641–6.
35. Ferreira D, Afonso MB, Rodrigues PM et al. c-Jun N-terminal kinase 1/c-Jun activation of the p53/microRNA 34a/sirtuin 1 pathway contributes to apoptosis induced by deoxycholic acid in rat liver. Mol Cell Biol 2014; 34: 1100–20.
36. Yoshimoto S, Loo TM, Atarashi K et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013; 499: 97–101.
37. Miele L, Valenza V, La Torre G et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1877–87.
38. Mouzaki M, Comelli EM, Arendt BM et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 2013; 58: 120–7.
39. Jahnel J, Zöhrer E, Alisi A et al. Serum bile acid levels in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2015; 61: 85–90.
40. Woolbright BL, Jaeschke H. Novel insight into mechanisms of cholestatic liver injury. World J Gastroenterol 2012; 18: 4985–93.
41. Nalapareddy P, Schüngel S, Hong JY, Manns MP, Jaeschke H, Vogel A. The BH3-only protein bid does not mediate death-receptor-induced liver injury in obstructive cholestasis. Am J Pathol 2009; 175: 1077–85.
42. Mitchell C, Mahrouf-Yorgov M, Mayeuf A et al. Overexpression of Bcl-2 in hepatocytes protects against injury but does not attenuate fibrosis in a mouse model of chronic cholestatic liver disease. Lab Invest 2011; 91: 273–82.
43. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842–5.
44. Syn WK, Choi SS, Diehl AM. Apoptosis and cytokines in non-alcoholic steatohepatitis. Clin Liver Dis 2009; 13: 565–80.